Article Type
Video
Changed
Thu, 12/15/2022 - 18:23
Display Headline
BOLERO-2: Overcoming Treatment Resistance in Breast Cancer

SAN ANTONIO – Dr. Howard Burris, Dr. William J. Gradishar, and Dr. Hope Rugo discuss the implications of the BOLERO-2 trial, which coupled everolimus with exemestane in women with advanced hormone resistant, estrogen receptor-positive breast cancer.

Author and Disclosure Information

Publications
Oncology Practice
MDedge Hematology and Oncology
Breast Cancer ICYMI
Topics
Breast Cancer
Legacy Keywords
everolimus exemestane, advanced hormone resistant, estrogen receptor-positive breast cancer, Dr. Howard Burris, Dr. Hope Rugo
Author and Disclosure Information

Author and Disclosure Information

SAN ANTONIO – Dr. Howard Burris, Dr. William J. Gradishar, and Dr. Hope Rugo discuss the implications of the BOLERO-2 trial, which coupled everolimus with exemestane in women with advanced hormone resistant, estrogen receptor-positive breast cancer.

SAN ANTONIO – Dr. Howard Burris, Dr. William J. Gradishar, and Dr. Hope Rugo discuss the implications of the BOLERO-2 trial, which coupled everolimus with exemestane in women with advanced hormone resistant, estrogen receptor-positive breast cancer.

Publications
Oncology Practice
MDedge Hematology and Oncology
Breast Cancer ICYMI
Publications
Oncology Practice
MDedge Hematology and Oncology
Breast Cancer ICYMI
Topics
Breast Cancer
Article Type
Video
Display Headline
BOLERO-2: Overcoming Treatment Resistance in Breast Cancer
Display Headline
BOLERO-2: Overcoming Treatment Resistance in Breast Cancer
Legacy Keywords
everolimus exemestane, advanced hormone resistant, estrogen receptor-positive breast cancer, Dr. Howard Burris, Dr. Hope Rugo
Legacy Keywords
everolimus exemestane, advanced hormone resistant, estrogen receptor-positive breast cancer, Dr. Howard Burris, Dr. Hope Rugo
Article Source

PURLs Copyright

Inside the Article